Although environmental factors such as pesticides or metals may contribute to α-synuclein aggregation, and the gastrointestinal microbiome may influence PD drug metabolism or clinical phenotypes of the disease (Simon et al., 2020), however, nucleic-acid based therapies promise potential novel routes and genetic target for modification of the disease pathology (Kulkarni et al., 2021). The gene discussed is SNCA; the disease is Parkinson disease.